Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K R Reeves

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
The American Journal of Nursing|September 1, 1974
Beware of Reye's syndromeK R Reeves
The American Journal of Nursing|January 1, 1970
Children's reactions to head injuriesK R Reeves
Kangogaku Zasshi|January 1, 1972
[Acute epiglottis--pediatric emergency]K R Reeves
RN|August 1, 1976
This CAT is a revolutionary scannerK R Reeves
The American Journal of Nursing|August 1, 1971
Acute epiglottitis--pediatric emergencyK R Reeves
Journal of Clinical Psychopharmacology|February 24, 2001
Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studiesP E Keck, K R Reeves, E P Harrigan, et al.
The Journal of Clinical Psychiatry|March 10, 2001
Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patientsM D Lesem, J M Zajecka, R H Swift, et al.
Psychopharmacology|June 13, 2001
Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trialD G Daniel, S G Potkin, K R Reeves, et al.
Current Medical Research and Opinion|January 17, 2008
Comment and reply: A double-blind study evaluating the long-term safety of varenicline for smoking cessationJohn G Spangler, K E Williams, K R Reeves, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 8, 1999
Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study GroupD G Daniel, D L Zimbroff, S G Potkin, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
The American Journal of Nursing|September 1, 1974
Beware of Reye's syndromeK R Reeves
The American Journal of Nursing|January 1, 1970
Children's reactions to head injuriesK R Reeves
Kangogaku Zasshi|January 1, 1972
[Acute epiglottis--pediatric emergency]K R Reeves
RN|August 1, 1976
This CAT is a revolutionary scannerK R Reeves
The American Journal of Nursing|August 1, 1971
Acute epiglottitis--pediatric emergencyK R Reeves
Journal of Clinical Psychopharmacology|February 24, 2001
Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studiesP E Keck, K R Reeves, E P Harrigan, et al.
The Journal of Clinical Psychiatry|March 10, 2001
Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patientsM D Lesem, J M Zajecka, R H Swift, et al.
Psychopharmacology|June 13, 2001
Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trialD G Daniel, S G Potkin, K R Reeves, et al.
Current Medical Research and Opinion|January 17, 2008
Comment and reply: A double-blind study evaluating the long-term safety of varenicline for smoking cessationJohn G Spangler, K E Williams, K R Reeves, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 8, 1999
Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study GroupD G Daniel, D L Zimbroff, S G Potkin, et al.
Pageof 2